Breakthrough in Renewable Energy: Solar Technology Surges Ahead
Alhemo® Receives Positive Recommendation for Haemophilia Treatment in Europe
Cell Therapy Advancements: Novo Nordisk and Evotec Partner for Next-Generation Treatments
Medicare Spending on Wegovy Could Surge by $145 Billion
Novo Nordisk Faces Continued its GLP-1 Therapy Ozempic Shortages Into Q4 2024 Amid Expanding Demand
Novo Nordisk Reports Strong Financial Growth in H1 2024, Driven by Diabetes and Obesity Treatments
Heart Failure Approval Delayed as Novo Nordisk Withdraws Wegovy FDA Submission
Insulin Product Halt by Novo Nordisk Sparks Campaign to Save Levemir for Diabetics
Insulin Icodec Receives FDA Complete Response Letter, Additional Data Required for Approval
Diabetes Drug Battle: Novo Nordisk Confronts Generic Competition for Ozempic and Wegovy in China
FDA Raises Hypoglycemia Concerns Over Novo Nordisk’s Weekly Insulin for Type 1 Diabetes
Wegovy Receives FDA Approval for Cardiovascular Events Reduction